MX2024004429A - Regimenes de dosificacion del anticuerpo anti-ctla-4. - Google Patents

Regimenes de dosificacion del anticuerpo anti-ctla-4.

Info

Publication number
MX2024004429A
MX2024004429A MX2024004429A MX2024004429A MX2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A MX 2024004429 A MX2024004429 A MX 2024004429A
Authority
MX
Mexico
Prior art keywords
ctla
dosing regimens
antibody dosing
antibody
regimens
Prior art date
Application number
MX2024004429A
Other languages
English (en)
Spanish (es)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Publication of MX2024004429A publication Critical patent/MX2024004429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024004429A 2021-10-29 2022-10-28 Regimenes de dosificacion del anticuerpo anti-ctla-4. MX2024004429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163273660P 2021-10-29 2021-10-29
PCT/US2022/078875 WO2023077069A1 (en) 2021-10-29 2022-10-28 Anti-ctla-4 antibody dosing regimens

Publications (1)

Publication Number Publication Date
MX2024004429A true MX2024004429A (es) 2024-05-06

Family

ID=86158833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004429A MX2024004429A (es) 2021-10-29 2022-10-28 Regimenes de dosificacion del anticuerpo anti-ctla-4.

Country Status (9)

Country Link
EP (1) EP4422685A4 (enExample)
JP (1) JP2024540152A (enExample)
KR (1) KR20240099187A (enExample)
CN (1) CN118176021A (enExample)
AU (1) AU2022377644A1 (enExample)
CA (1) CA3234351A1 (enExample)
MX (1) MX2024004429A (enExample)
TW (1) TW202325738A (enExample)
WO (1) WO2023077069A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121358769A (zh) * 2023-05-17 2026-01-16 昂科医药 Ph敏感性抗ctla-4抗体及其用途
WO2026041780A2 (en) * 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110194B2 (en) * 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP2021513540A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法

Also Published As

Publication number Publication date
EP4422685A1 (en) 2024-09-04
CA3234351A1 (en) 2023-05-04
EP4422685A4 (en) 2025-12-03
AU2022377644A1 (en) 2024-05-16
KR20240099187A (ko) 2024-06-28
CN118176021A (zh) 2024-06-11
JP2024540152A (ja) 2024-10-31
WO2023077069A1 (en) 2023-05-04
TW202325738A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MX2020006668A (es) Anticuerpos para lilrb2.
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2025002661A (es) Composiciones anti-cd24 y usos de las mismas
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2024000614A (es) Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer.
MY195110A (en) Antibodies to PD-1 and uses Thereof
ZA202005388B (en) Methods of treating ulcerative colitis
JOP20200003A1 (ar) أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعة
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
TW201713698A (en) PD-1 antibodies
PH12016500137B1 (en) Afucosylated anti-fgfr2iiib antibodies
PH12019550233A1 (en) A novel anti-c-met antibody and use thereof
PH12022550246A1 (en) A dosing regimen for an ido inhibitor
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
MX2019002728A (es) Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
MX2021005236A (es) Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2024004429A (es) Regimenes de dosificacion del anticuerpo anti-ctla-4.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof